ROLE OF MECHANISMS OF VIOLATIONS proliferation and apoptosis in morphogenesis fibrocystic disease of breast

Cover Page


Cite item

Full Text

Abstract

In this paper, an analysis of published data shows the significant role of apoptosis during ontogenesis of the breast, the neoplastic transformation of tissues and the likely importance of these processes in the mechanism of hyperplastic processes and fibrocystic disease of breast cancer. However, it remains unresolved the question of what biological markers may serve as quantitative indicators of proliferative activity of breast tissue, as well as objectively reflect the severity of apoptosis and the activity of genes - tumor suppressor. Studying the expression of molecules of products of genes-regulators of cell proliferation and apoptosis is of great scientific interest because it can probably afford to hold detalizovannye risk assessment for breast cancer, followed by the prediction of the disease

References

  1. Аничков Н.М. Биология опухолевого роста: молекулярно-медицинские аспекты / Н.М. Аничков, И.М. Кветной, С.С. Коновалов. - СПб.: Прайм Еврознак, 2004. - 224 с.
  2. Белушкина Н.Н. Молекулярные основы патологии апоптоза / Н.Н. Белушкина, С.Е. Северин // Арх. пат. - 2001. - Вып. 1. - С. 51-59.
  3. Берштейн Л.М. Онкоэндокринология: традиции, современность и перспективы / Л.М. Берштейн. - СПб.: Наука, 2004. - 343 с.
  4. Божок А.А. Прогностические и предсказательные факторы при раке молочной железы /А.А. Божок, В.Ф. Семиглазов, В.В. Семиглазов, А.С. Арзуманов, А.Е. Клетцель // Вопр. Онкол. - 2005. -Т. 51, №4. - С. 434-443.
  5. Золотова Е.Н. Современные аспекты морфогенеза рака молочной железы / Е.Н. Золотова, А.Е. Доросевич//Арх. патол. - 2004. - №1 - С. 51-55.
  6. Коршунов А.Г. Прогностическое значение иммуногистохимического выявления апоптоза и экспрессии белков лекарственной устойчивости / А.Г. Коршунов, Р.В. Сычева // Арх. патол. - 1996. - №2. - С. 32-37.
  7. Костючек И.Н. Методологические подходы к количественной иммуногистохимической оценке экспрессии маркеров апоптоза и пролиферации в молочной железе / И.Н. Костючек, И.Ю. Коган, И.М. Кветной // Арх. патол. - 2006. - №1. - С. 47-48.
  8. Молекулярно-биологические маркеры как факторы прогноза при раке молочной железы / Е.В. Степанова, Е.И. Загрекова, В.Д. Ермилова [и др.] // Арх. патол. -2003. - №3. - С. 14-18.
  9. Нейштадт Э.Л. Патология молочной железы / Э.Л. Нейштадт, О.А. Воробьева. - СПб.: Фолиант, 2003. - 208с.
  10. Пожарийский К.М. Значение иммуногистохимических методик для определения характера лечения и прогноза опухолевых заболеваний / К.М. Пожарийский, Е.Е. Леенман // Арх. патол. - 2000. - №5. - С 3-11.
  11. Райхлин Н.Т. Регуляция и проявления апоптоза в физиологических условиях и в опухолях / Н.Т. Райхлин, А.Н. Райхлин // Вопр. Онкол. - 2002. - Т.48, №2. - С . 159-171.
  12. Семиглазов В.Ф. Неинвазивные и инвазивные опухоли молочной железы / В.Ф. Семиглазов, В.В. Семиглазов, А.Е. Клецель. - СПб.: Боргес, 2005. - 350 с.
  13. Серов В.Н. Диагностика заболеваний молочных желез / В.Н. Серов, Т.Т. Тагиева, В.Н. Прилепская // Гинекология. - 1999. - №1. - С. 6-10.
  14. Упоров А.В. Иммуногистохимическое изучение клеток рака молочной железы с использованием разных маркеров пролиферации / А.В. Упоров В.Ф. Семиглазов, К.М. Пожарийсский // Арх. патол. - 2000. - №2. - С. 26-30.
  15. Хансон К.П. Программированная клеточная гибель (апоптоз): молекулярные механизмы и роль в биологии и медицине / К.П. Хансон // Вопр. мед. химии. 1997. - Т. 43, №5. - С. 402-414.
  16. Шацева Т.А. Антиген Ki-67 в оценке опухолевой пролиферации. Его структура и функции / Т.А. Шацева, М.С. Мухина // Вопр. Онкол. - 2004. - Т.50,№2.-С. 157-164.
  17. Экспрессия HER-2/NEU, KI-67 и плоидность при раке молочной железы / М.И. Лукашина, Е.И. Глухова, Л.Г. Жукова [и др.] // Арх. патол. - 2003. - №5. - С. 25-29.
  18. Anderson TJ. Pathological studies of apoptosis in the normal breast / Anderson T.J. // Cancer. - 1999. - Vol. 6. - P. 9-12.
  19. Assessment of the proliferative, apoptotic and cellular renovation indices of the human mammary epithelium during the follicular and luteal phases of the menstrual cycle / NavarreteM.A., Maier СМ., Falzoni R. [et al.] // Breast Cancer Research. - 2005. - Vol. 7. - P. 306-313.
  20. Beenken S.W. Biomarkers for breast cancer / Beenken S.W., Bland K.I. // Minerva Chir. - 2002. - Vol. 57, N 4. - P. 437-448.
  21. Bykov V. Reactivation of mutant p53 and induction of apoptosis in human tumor cells bymaleimide analogs / Bykov V., Issaeva N., Zache N. [et al.] // J. Biol. Chem. -2005. - Vol.34. - P. 30384 - 30391.
  22. Dimitrakakis C, Konstadoulakis M., Messaris E., Kymionis G., Karayannis M., Panoussopoulos D., Michalas S., Androulakis G. Molecular markers in breast cancer: Can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? // The Breast. - 2005 - Vol. 11, № 4. - P. 279-285.
  23. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo/
  24. Krajewski S., Bodrug S., KrajewskaM. [et al.]//Am. J. Pathol. - 1995. - Vol.146, N 6.-P.1309-1319.
  25. Cardillo M.R. Proliferating cell nuclear antigen in benign breast diseases / Cardillo M.R., Stamp G.W., Pignatelli M. // Eur. J. Gynaecol. Oncol. - 1995. - Vol. 16, N6. -P. 476-481.
  26. Castro-Rivera E. Estrogen regulation of cyclin Dl gene expression in ZR-75 breast cancer cells involves multiple enhancer elements / Castro-Rivera E.,
  27. Claus E.B. Age at onset as an indicator of familial risk of breast cancer / Claus E.B., RischNJ., Thompson W.D. //Am. J. Epidemiol.-1990.-Vol. 131.-P. 961- 972.
  28. Conner P. Breast epithelial proliferation in postmenopausal women evaluated through fine-needle-aspiration cytology / Conner P., Skoog L., Soderqvist G. // Climacteric. - 2007. - Vol. 4, № 1. - p. 7-12.
  29. Cuzick J. Aromatase inhibitors in prevention - data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study) / Cuzick J.// Recent Results Cancer Res.-2003 .-Vol. 163 .-P. 96-103.
  30. Differentiation between cancerous and normal hyperplastic lobules in breast lesions / Slater M., Danieletto S., Pooley M. [et al.] // Breast Cancer Res. Treat. - 2004. -Vol. 83, № 1. - P. 1-10.
  31. Going J.J. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles / Going J.J., Anderson T.J., Battersby S., Maclntyre C.C. // Am. J. Pathol. - 2008. - Vol. 130. - P. 193-204.
  32. Hasebe T. Proliferative activity and tumor angiogenesis closely correlated to stromal cellularity of fibroadenoma: proposal fibroadenoma, cellular variant / Hasebe Т., Imoto S., Sasaki S. // Pathol. Int. - 1999. - Vol. 49, N 5. - P. 435-443.
  33. Hofseth L.J. Hormone replacement therapy with estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast / Hofseth L.J., Raafat A.M., Osuch J.R. [et al.] // J. Clin. Endocrinol. Metab. - 2009. - Vol. 84, N 12. - P. 4559-4565.
  34. Joshi K. Cell proliferation in the human mammary epithelium. Differential contribution by epithelial and myoepithelial cells / Joshi K., Smith J.A., Perusinghe N., Monoghan P. // Am. J. Pathol. - 1986. - Vol. 124, №2. - P.199- 206.
  35. Loughlin P.M., Cooke T.G., George W.D., Gray A.J., Stott D.I., Going J.J. 35. Quantifying tumour-infiltrating lymphocyte subsets: A practical immunohistochemical method // J Immunol Methods. - 2007. - Vol.321, №1-2. - P.32-40.
  36. Matsuyoshi S., Shimada K., Nakamura M., Ishida E., Konishi N. Bcl-2 phosphorylation has pathological significance in human breast cancer // Pathobiology. - 2006. - Vol. 73, №4. - P. 205-212.
  37. Midulla C, Pisani I., De Iorio P., Cenci M., Divizia E., Nofroni I., Vecchoone A. Cythological analysis and immunocytochemical expression of Ki-67 and Bcl-2 in breast proliferative lesions // Anticancer Res. - 2002. - Vol. 22, № 2. - P . 1641-1345.
  38. Minelli C. Benefits and harms associated with hormone replacement therapy: clinical decision analysis / Minelli C, Abrams K.R., Sutton A.J., Cooper NJ. // BMJ. - 2004. - Vol. 328, N 7436. - P. 371-385.
  39. Ohmichi M. Molecular mechanism of action of selective estrogen receptor modulator in target tissues / Ohmichi M., Tasaka K., Kurachi H., Murata Y. // Endocr. J.-2005.-Vol. 52.-P. 161-167.
  40. Pechoux C. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells / Pechoux C, Gudjonsson Т., Ronnov-Jessen L., Bissell M.J. // Dev. Biol. - 1999. - Vol. 206, № 1. - P. 88 - 99.
  41. McLaughlin R., Prognostic implications of p53 and bcl-2 expression in 108 women with stage two breast cancer / McLaughlin R., O'Hanlon D., McHale T. [et al.] // Int. J. Med. Sci.-2001.-Vol. 170.-P. 11-13.
  42. Potten C.S., Watson R.J., Williams G.T., Tickle S., Roberts S.A., Harris M., Howell A. The effect of age and menstrual cycle upon proliferative activity of the normal human breast // Br J. Cancer. - 1988. - Vol. 58., №2. a. 163-170.
  43. Rescue of mutants of the tumor suppressor p53 in cancer cells by designed peptide Issaeva N., Friedler A., Bozko P. [et al.] // Cell boil. - 2003. - Vol. 100, № 23. - P. 13303-13307.
  44. Risk factors for benign proliferative breast disease / Friedenreich СМ., Bryant H.M., Alexander F. [et al.] // International Journal of Epidemiology. - 2000. - Vol. 29, №4. - 637 - 644.
  45. Risk factors for breast cancer according to estrogen and progesterone receptor status / Colditz G.A., Rosner B.A., Chen W.Y. [et al.] // J. Natl. Cancer Inst- 2004.-Vol. 96.-P. 218-228.
  46. Selim A.G. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing agenesis of the breast / Selim A.G., El-Ayat G., Wells С A. // Virchows Arch. - 2002. - Vol. 441, N 5. - P. 449-455.
  47. Speirs V. Distinct expression patterns of ERor and ERB in normal human mammary gland / Speirs V., Skliris G.P., Burdall S.E., Carder P.J. // J. Clin. Pathol. - 2009. - Vol. 55. - P. 371-374.
  48. Stoll B.A. Premalignant breast lesions: role for biological markers in predicting progression to cancer / Stoll B.A. // Eur. J. Cancer. - 2009. - Vol. 35, N 5. - P. 693-697.
  49. Siziopiku K.P. bcl-2 expression in the spectrum of preinvasive breast lesions/Siziopiku K.P., Prioleau J.E., Harris J.R., Schnitt SJ.//Cancer. - 1996.- Vol.77. -P.499-506.
  50. Sullivan R.P. Cell proliferation in breast tumours: analysis of histological parameters Ki-67 and PCNA expression / Sullivan R.P., Mortimer G., Muircheartaigh I.O. // Ir. J. Med. Sci. - 1993. - Vol. 162, N 9. - P. 343-347.
  51. Cell proliferation, apoptosis and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history / Feuerhake F., Sigg W., Hofter E.A. [et al.] // Breast Cancer Res. Treat. - 2003.-Vol. 77, № 1.-P. 37-48.
  52. Tung L., Abdel-Hafiz H., Shen Т., Harvell D.M., et al. Progesterone receptors (PR)-B and PR-A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B // Molec. Endocrinol. - 2006. - Vol. 20, № 11. - P. 2656 - 2от когана.
  53. Feuerhake F., Sigg W., Hofter E.A., Unterberger P., Welsh H. Cell proliferation, apoptosis and expression of Bcl-2 and Bax in non-lactating human breast epithelium in relation to the menstrual cycle and reproductive history // Breast Cancer Res. Treat. - 2003. - Vol. 77, № 1. - P. 37-48.
  54. Zagouri F. Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma / Zagouri F.,Sergentanis T.N., Zografos G.C. // World J. Surg. Oncol. - 2007. - Vol.5, N. 57.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Mnikhovich M.V., Mnikhovich M.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Media Registry Entry of the Federal Service for Supervision of Communications, Information Technology and Mass Communications (Roskomnadzor) PI No. FS77-76803 dated September 24, 2019.



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies